BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BIOGEN INC.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Jul 29, 2026
$233.48+0.83 (+0.36%)
Close on Oct 19, 2026
- Market cap
- $34.65B
- P/E (TTM)
- 25.1
- Dividend yield
- –
Biogen statistics
Financials through Mar 31, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Biogen | Industry median |
|---|---|---|
| Market Cap | $34.50B | $166.30M |
| Enterprise Value | $30.21B | $87.12M |
| PE Ratio | 25.05 | 19.67 |
| PS Ratio | 3.47 | 3.60 |
| P/FCF Ratio | 14.24 | 17.44 |
| P/OCF Ratio | 13.32 | 13.32 |
Enterprise value
| Measure | Biogen | Industry median |
|---|---|---|
| EV / Sales | 3.04 | 2.43 |
| EV / EBITDA | 11.19 | 14.69 |
| EV / FCF | 12.47 | 20.97 |
Income (trailing twelve months)
| Measure | Biogen | Industry median |
|---|---|---|
| Revenue | $9.94B | $57.94M |
| Gross Profit | $7.50B | $90.47M |
| Pretax Income | $1.62B | -$14.72M |
| Net Income | $1.37B | -$22.46M |
| EBITDA | $2.70B | -$17.14M |
| EPS (Diluted) | $9.32 | -$0.83 |
Margins
| Measure | Biogen | Industry median |
|---|---|---|
| Gross Margin | 75.5% | 52.3% |
| Pretax Margin | 16.3% | -13.0% |
| Profit Margin | 13.8% | -39.2% |
| EBITDA Margin | 27.2% | -31.3% |
| FCF Margin | 24.4% | -8.85% |
Returns
| Measure | Biogen | Industry median |
|---|---|---|
| Return on Assets (ROA) | 4.77% | -41.0% |
Growth
| Measure | Biogen | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 1.23% | 6.01% |
| Net Income Growth (YoY) | -7.26% | -37.7% |
| EPS Growth (YoY) | -8.00% | -29.2% |
| FCF Growth (YoY) | -0.57% | 2.34% |
| Revenue Growth (3Y CAGR) | -0.94% | 2.25% |
| Revenue Growth (5Y CAGR) | -5.96% | 6.42% |
| EPS Growth (3Y CAGR) | -25.0% | -0.17% |
| EPS Growth (5Y CAGR) | -18.7% | 3.77% |
Balance sheet
| Measure | Biogen | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $4.28B | $62.64M |
| Net Cash (Debt) | $4.28B | $15.77M |
| Net Cash Per Share | $28.99 | $0.66 |
| Working Capital | $6.19B | $75.09M |
Financial position
| Measure | Biogen | Industry median |
|---|---|---|
| Current Ratio | 3.06 | 3.30 |
| Quick Ratio | 1.43 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Biogen | Industry median |
|---|---|---|
| Operating Cash Flow | $2.59B | -$12.39M |
| Capital Expenditures | -$167.90M | -$1.07M |
| Free Cash Flow | $2.42B | -$20.34M |
| FCF Per Share | $16.40 | -$0.42 |
Efficiency
| Measure | Biogen | Industry median |
|---|---|---|
| Asset Turnover | 0.35 | 0.38 |
| Inventory Turnover | 1.15 | 2.67 |
| Revenue Per Employee | $1.32M | $398.96K |
| Profits Per Employee | $182.92K | -$705.27K |
| Employee Count | 7,500 | 74 |
Dividends and yields
| Measure | Biogen | Industry median |
|---|---|---|
| Earnings Yield | 3.98% | -22.8% |
| FCF Yield | 7.02% | -9.02% |
Shares
| Measure | Biogen | Industry median |
|---|---|---|
| Shares Outstanding | 147,754,000 | 58,139,000 |
| Shares Change (YoY) | 1.03% | 11.1% |
| Float | 147,447,000 | 49,154,900 |
| Shares Held by Insiders | 0.21% | 11.6% |
| Shares Held by Institutions | 96.3% | 59.4% |
Taxes
| Measure | Biogen | Industry median |
|---|---|---|
| Income Tax | $251.10M | $89.00K |
| Effective Tax Rate | 15.5% | 20.5% |
Scores
| Measure | Biogen | Industry median |
|---|---|---|
| Altman Z-Score | 3.49 | -0.27 |
| Piotroski F-Score | 4 | 4 |
| Beneish M-Score | -2.67 | -2.62 |
Calculated by StockData from Biogen's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.